Valuation: Geron Corporation

Market Cap 771M 687M 637M 579M 1.09B 73.1B 1.1B 7.64B 3B 38.2B 2.89B 2.83B 122B P/E 2026 *
-28.6x
P/E 2027 * 17.6x
Enterprise Value 771M 687M 637M 579M 1.09B 73.1B 1.1B 7.64B 3B 38.2B 2.89B 2.83B 122B EV / Sales 2026 *
3.26x
EV / Sales 2027 * 2.25x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+2.56%
1 week-1.64%
Current month-2.44%
1 month-7.69%
3 months-16.67%
6 months-28.57%
Current year-9.09%
1 week 1.17
Extreme 1.17
1.24
1 month 1.17
Extreme 1.17
1.33
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Free

Director

6,351 0.0010%
6/30/26 Free

Director

6,103 0.0010%
5/20/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+2.56%-1.64%0.00%-32.20% 752M
+1.52%-7.19%+51.66%+69.99% 65B
+1.52%+6.83%+10.77%+79.30% 51.2B
+0.30%-0.46%+2.53%+61.89% 51.19B
-0.38%+1.40%+29.98%+42.37% 43.93B
+0.30%+5.64%+16.99%+133.30% 41.96B
+2.35%-6.08%+236.69%+528.10% 38.14B
+2.16%+9.87%+18.92%+59.70% 33.24B
+3.53%-2.52%+38.93%+8.37% 25.2B
+1.60%+2.21%+21.34%+28.00% 22.5B
Average +1.56%-0.20%+42.78%+97.88% 37.31B
Weighted average by Cap. +1.28%-0.16%+46.06%+113.04%

Financials

2026 *2027 *
Net sales 236M 211M 195M 177M 333M 22.4B 338M 2.34B 920M 11.71B 886M 868M 37.43B 342M 305M 282M 257M 482M 32.42B 490M 3.39B 1.33B 16.95B 1.28B 1.26B 54.17B
Net income -27.18M -24.23M -22.44M -20.41M -38.29M -2.58B -38.92M -269M -106M -1.35B -102M -99.85M -4.31B 50.14M 44.7M 41.41M 37.65M 70.64M 4.75B 71.81M 497M 195M 2.48B 188M 184M 7.94B
Net Debt - -
Projected Income Statement - Annual - Geron Corporation
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-10-19 $1.200 +2.56% 4,909,386
26-10-16 $1.170 -4.88% 3,957,991
26-10-15 $1.230 +3.36% 5,678,554
26-10-14 $1.190 -0.83% 5,428,739
26-10-13 $1.200 -1.64% 7,578,160
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Geron Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.200USD
Average target price
4.250USD
Spread / Average Target
+254.17%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Geron Corporation
  1. Stock Market
  2. Stocks
  3. GERN Stock